Cytokinetics have published a press release of their ‘top line’ results for their drug Tirasemtiv. Unfortunately, the results are disappointing.
The main aim of their most recent clinical trials was to see if there was a slower rate of progression (measured by a widely used MND clinical scale called the ALSFRS) in people with MND taking tirasemtiv compared to those taking the dummy drug. The researchers didn’t find any difference in ALSFRS scores. They’re currently analysing the results for beneficial effects on other symptoms of MND.
The full results will be presented at the American Academy of Neurology conference next week. Sam is working on a more detailed article after these have been presented. More information about tirasemtiv can be found on our website. The press release announcing these ‘top line’ results can be found here.
Dr Belinda Cupid, Head of Research at the MND Association said: “MND clinical trials give us all new hope that something can be done to slow the progression of the disease, and it’s devastating when those trials don’t show any benefit. It emphasizes why we have to continue to fund research – finding the cause and source of the disease and then working out how to stop it.”